JP2013506715A5 - - Google Patents

Download PDF

Info

Publication number
JP2013506715A5
JP2013506715A5 JP2012533248A JP2012533248A JP2013506715A5 JP 2013506715 A5 JP2013506715 A5 JP 2013506715A5 JP 2012533248 A JP2012533248 A JP 2012533248A JP 2012533248 A JP2012533248 A JP 2012533248A JP 2013506715 A5 JP2013506715 A5 JP 2013506715A5
Authority
JP
Japan
Prior art keywords
nitrogen
oxygen
membered
ring
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012533248A
Other languages
English (en)
Japanese (ja)
Other versions
JP6016635B2 (ja
JP2013506715A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/051517 external-priority patent/WO2011044157A1/en
Publication of JP2013506715A publication Critical patent/JP2013506715A/ja
Publication of JP2013506715A5 publication Critical patent/JP2013506715A5/ja
Application granted granted Critical
Publication of JP6016635B2 publication Critical patent/JP6016635B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012533248A 2009-10-06 2010-10-05 Ｐｄｋ１インヒビターとして有用な複素環式化合物 Expired - Fee Related JP6016635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24909509P 2009-10-06 2009-10-06
US61/249,095 2009-10-06
PCT/US2010/051517 WO2011044157A1 (en) 2009-10-06 2010-10-05 Heterocyclic compounds useful as pdk1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016155272A Division JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Publications (3)

Publication Number Publication Date
JP2013506715A JP2013506715A (ja) 2013-02-28
JP2013506715A5 true JP2013506715A5 (enExample) 2013-11-14
JP6016635B2 JP6016635B2 (ja) 2016-10-26

Family

ID=43857093

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012533248A Expired - Fee Related JP6016635B2 (ja) 2009-10-06 2010-10-05 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2016155272A Withdrawn JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2018106041A Pending JP2018145196A (ja) 2009-10-06 2018-06-01 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2020149736A Withdrawn JP2020203925A (ja) 2009-10-06 2020-09-07 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2022177407A Pending JP2023002840A (ja) 2009-10-06 2022-11-04 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016155272A Withdrawn JP2016188253A (ja) 2009-10-06 2016-08-08 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2018106041A Pending JP2018145196A (ja) 2009-10-06 2018-06-01 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2020149736A Withdrawn JP2020203925A (ja) 2009-10-06 2020-09-07 Ｐｄｋ１インヒビターとして有用な複素環式化合物
JP2022177407A Pending JP2023002840A (ja) 2009-10-06 2022-11-04 Ｐｄｋ１インヒビターとして有用な複素環式化合物

Country Status (27)

Country Link
US (6) US9546165B2 (enExample)
EP (3) EP3466929B1 (enExample)
JP (5) JP6016635B2 (enExample)
KR (3) KR20120087936A (enExample)
CN (1) CN102665718B (enExample)
AR (2) AR078540A1 (enExample)
AU (3) AU2010303567B2 (enExample)
BR (1) BR112012007747B8 (enExample)
CA (1) CA2776690C (enExample)
CY (1) CY1118143T1 (enExample)
DK (2) DK3070077T3 (enExample)
ES (2) ES2586856T3 (enExample)
HR (1) HRP20160967T1 (enExample)
HU (2) HUE028082T2 (enExample)
IL (4) IL295518B2 (enExample)
IN (1) IN2012DN03883A (enExample)
LT (1) LT2485731T (enExample)
MX (2) MX389288B (enExample)
PH (1) PH12012500674A1 (enExample)
PL (1) PL2485731T4 (enExample)
PT (1) PT2485731T (enExample)
RS (1) RS55101B1 (enExample)
RU (2) RU2615130C2 (enExample)
SI (1) SI2485731T1 (enExample)
SM (1) SMT201600275B (enExample)
TW (1) TWI525093B (enExample)
WO (1) WO2011044157A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376485B1 (en) 2008-12-19 2017-12-06 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
DK3070077T3 (en) 2009-10-06 2019-04-01 Millennium Pharm Inc HETEROCYCLIC COMPOUNDS USING PDK1 INHIBITORS
EP2569286B1 (en) * 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
KR20130066633A (ko) 2010-05-12 2013-06-20 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
US9321735B2 (en) 2010-07-20 2016-04-26 Vestaron Corporation Insecticidal triazines and pyrimidines
WO2012034526A1 (en) * 2010-09-16 2012-03-22 Hutchison Medipharma Limited Fused heteroaryls and their uses
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
BR112014007690B1 (pt) 2011-09-30 2022-10-04 Vertex Pharmaceuticals Incorporated Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas
CN103987709B (zh) 2011-09-30 2016-09-28 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
CN103159741B (zh) * 2011-12-19 2016-08-24 天津市国际生物医药联合研究院 一类酪氨酸激酶抑制剂的制备和用途
EP3311816A1 (en) 2012-04-05 2018-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase for the treatment of cancer
CN102627632B (zh) * 2012-04-16 2014-06-18 中国科学院广州生物医药与健康研究院 一种胺基喹唑啉衍生物及其制备方法和用途
WO2013161913A1 (ja) 2012-04-25 2013-10-31 武田薬品工業株式会社 含窒素複素環化合物
WO2013169889A1 (en) * 2012-05-08 2013-11-14 Anvyl Llc Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20150135332A (ko) * 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
MY172600A (en) * 2013-05-31 2019-12-05 Nissan Chemical Ind Ltd Heterocyclic amide compound
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
EP3026051A4 (en) 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
EA035727B1 (ru) 2013-10-18 2020-07-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы бромодомена
WO2015073804A2 (en) * 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
EP3071206B1 (en) 2013-11-22 2021-02-17 CL Biosciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
CN104130256B (zh) * 2014-08-01 2016-08-24 上海毕得医药科技有限公司 一种吡啶并[3,4-d]嘧啶-4（3H）-酮衍生物的制备方法
WO2016064957A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
PL3218378T3 (pl) 2014-11-14 2020-10-19 Nerviano Medical Sciences S.R.L. Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
CN105130980B (zh) * 2015-09-09 2018-05-22 沈阳药科大学 N-3-苯并咪唑噻唑胺类衍生物及其制备方法与应用
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
RU2768621C1 (ru) 2015-09-30 2022-03-24 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr
KR101753652B1 (ko) * 2015-10-21 2017-07-05 한국화학연구원 N-아릴-1h-피라졸로피리딘-3-아민 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
KR101753654B1 (ko) 2015-10-21 2017-07-05 한국화학연구원 3-(4-(피페라진-1-일)벤즈아미도)-1h-피라졸로피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 melk 관련 질환의 예방 또는 치료용 약학적 조성물
US20190015410A1 (en) * 2015-10-23 2019-01-17 Sunesis Pharmaceuticals, Inc. Heterocyclic pdk1 inhibitors for use to treat cancer
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
PT3436461T (pt) 2016-03-28 2024-01-23 Incyte Corp Compostos de pirrolotriazina como inibidores de tam
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
BR112019003504A2 (pt) 2016-08-24 2019-05-21 Arqule, Inc. compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
WO2018119208A1 (en) 2016-12-22 2018-06-28 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
WO2018164248A1 (ja) * 2017-03-10 2018-09-13 大塚化学株式会社 反応生成物及びゴム組成物
ES2949402T3 (es) * 2017-06-09 2023-09-28 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de la histona metiltransferasa
WO2019094779A1 (en) * 2017-11-09 2019-05-16 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
CA3088548A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
CN109087534A (zh) * 2018-10-09 2018-12-25 王业宝 一种基于车辆行驶轨迹的交通冲突检测方法
KR102293339B1 (ko) * 2019-04-17 2021-08-25 이화여자대학교 산학협력단 아미노알코올을 포함하는 아민 화합물에 대한 형광 및/또는 원편광 이색성 센서용 신규 프로브 화합물, 및 이를 이용한 형광 및 원편광 이색성 동시 분석 방법
CN110066221B (zh) * 2019-05-16 2022-03-08 海门瑞一医药科技有限公司 一种环丙基甲胺的制备方法
WO2021064141A1 (en) * 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
JP7371253B2 (ja) * 2019-11-25 2023-10-30 デウン ファーマシューティカル カンパニー リミテッド 新規なトリアゾロピリジン誘導体およびこれを含む薬学組成物
CN114685491B (zh) * 2020-12-31 2024-01-12 清华大学 吡啶-2-胺衍生物及其药物组合物和用途
AR127972A1 (es) * 2021-12-17 2024-03-13 Pi Industries Ltd Novedosos compuestos de piridina carboxamida bicíclica sustituida fusionada para combatir hongos fitopatogénicos
US20250163044A1 (en) * 2021-12-24 2025-05-22 Psylo Pty Ltd Compounds
WO2024040241A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
WO2024040242A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Combinations of pdk1 inhibitors and kinase inhibitors
TW202506116A (zh) * 2023-04-21 2025-02-16 美商凱麥拉醫療公司 Tyk2降解劑及其用途
CN117603068A (zh) * 2023-08-01 2024-02-27 常州寅盛药业有限公司 一种氨甲环酸的制备方法
WO2025076290A1 (en) * 2023-10-05 2025-04-10 Purdue Research Foundation 5-6-5/6-bisaryl compounds as flt3 inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175980A (en) * 1958-05-23 1965-03-30 Geigy Ag J R Compositions of matter of improved appearance in daylight, containing a 3.5-diaminopyrazine-2.6-dicarboxylic acid derivative
PL114780B1 (en) * 1978-03-10 1981-02-28 Inst Przemyslu Farmaceutic Process for preparing novel alkylamides of 2-anilinonicotinic acids
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
ATE326453T1 (de) 1998-12-23 2006-06-15 Lilly Co Eli Antithrombotische amide
DE69907963T2 (de) * 1998-12-23 2004-05-19 Eli Lilly And Co., Indianapolis Heteroaromatische amide als inhibitoren von faktor xa
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
EP1501514B1 (en) * 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CN100447139C (zh) 2003-07-08 2008-12-31 诺瓦提斯公司 苯磺酰氨基化合物和含有这些化合物的药物组合物
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050182061A1 (en) * 2003-10-02 2005-08-18 Jeremy Green Phthalimide compounds useful as protein kinase inhibitors
EP1680401A2 (en) * 2003-10-24 2006-07-19 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
AR049418A1 (es) * 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
CA2610509A1 (en) 2005-06-03 2006-12-14 Bayer Healthcare Ag 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
EP1979353A2 (en) * 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
JP5523829B2 (ja) * 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
WO2008016643A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US7915287B2 (en) * 2006-12-20 2011-03-29 Amgen Inc. Substituted heterocycles and methods of use
US7705018B2 (en) * 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
AU2008266883B2 (en) * 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
CN102573486A (zh) * 2009-06-08 2012-07-11 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
DK3070077T3 (en) 2009-10-06 2019-04-01 Millennium Pharm Inc HETEROCYCLIC COMPOUNDS USING PDK1 INHIBITORS

Similar Documents

Publication Publication Date Title
JP2013506715A5 (enExample)
RU2012118667A (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
Mokale et al. Synthesis and anti-inflammatory activity of some 3-(4, 6-disubtituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidin-5-yl) propanoic acid derivatives
AU2015355839B2 (en) Heterocyclic derivatives and use thereof
JP2015532295A5 (enExample)
JP2013503905A5 (enExample)
JP2016509047A5 (enExample)
JP2014503567A5 (enExample)
BR112013026137B1 (pt) pirimidinil-pirróis substituídos ativos como inibidores da quinase
RU2010147404A (ru) Замещенные дигидропиразолоны в качестве ингибиторов hif-пролил-4-гидроксилазы
US8822732B2 (en) 1,5-diphenyl-penta-1,4-dien-3-one compounds
JP2009530424A5 (enExample)
KR20130099064A (ko) (아자)인돌리진 유도체 및 그 의약용도
JP2012504608A5 (enExample)
JP2024515062A (ja) 重水素化ｄｈｏｄｈ阻害剤
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2024096821A (ja) 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸
JP2016525104A5 (enExample)
KR101648377B1 (ko) 축합환 유도체 및 그 의약용도
JP2010510216A5 (enExample)
AU2012236275B2 (en) Derivatives of sulindac, use thereof and preparation thereof
JPWO2005080322A1 (ja) フルオレン誘導体
JP2018538244A5 (enExample)
JP2025500176A (ja) カルボン酸バイオアイソスタを含むｄｈｏｄｈ阻害剤
DK168861B1 (da) 4-methyl-5-(2-(4-phenyl-1-piperazinyl)ethyl)thiazolderivater og fremgangsmåde til fremstilling deraf, farmaceutiske midler indeholdende thiazolderivaterne og fremgangsmåde til fremstilling deraf og anvendelse af derivaterne til fremstilling af lægemidler